LiSAVIOR Placed on High Priority Status: Recruitment of Clinical Study Volunteer Names Begin
Dr. Roger Kenneth Hershline PhD MD, CEO Global Humanceuticals, Inc. announced today that he has placed LiSAVIOR, an HIV drug in their development pipeline, into his company's High Priority status. Global Humanceuticals is highly interested to hear from prospective clinical trial participants from both the professional or treating group and the subject or treatment group.
Hilton Head Island, SC (PRWEB) May 22, 2008 -- Dr. Roger Kenneth Hershline PhD MD, CEO Global Humanceuticals, Inc. http://www.CureHIV.us announced today that he has placed LiSAVIOR, an HIV drug in their development pipeline, into his company's High Priority status. This means that work on LiSAVIOR drug development may increase by a factor of ten. The previous status, of "WLSWH status or Well Let's See What Happens is history" stated Dr. Hershline. Dr. Hershline stated that he has been very impressed by his new gastrointestinal treatment theory of the HIV reservoir. The theory states that in order to efficiently treat, prevent or cure HIV, that an anti-HIV compound must be present in the entire gastrointestinal tract. "LiSAVIOR, has the potential to fulfill this need and must be tested" declared Dr. Hershline at this high level meeting. Dr. Hershline will be releasing videos as this campaign progresses. Each subsequent video will be improved in quality and content until all of the information is exhaustively repeated. The goal is to promote this concept in the scientific and potential patient populations. Recruitment of study volunteers will be conducted in an ethical fashion and it is important to reach as many people as possible to make this fair, balanced and of course successful. Global Humanceuticals is highly interested to hear from prospective clinical trial participants from both the professional or treating group and the subject or treatment group.
As the founder of the CureHIV foundation, Dr. Hershline hopes this new High Priority status will help overcome the roadblocks that have prevented the completion of preclinical studies that are required by the FDA and get LiSAVIOR directed into the clinical studies where it is needed.
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1Mb3ZlLUNvdXAtSG9yci1DcmFzLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.